Kiora Pharmaceuticals Inc expected to post a loss of 42 cents a share - Earnings Preview

Kiora Pharmaceuticals

19/03/2024 12:55

* Kiora Pharmaceuticals Inc  KPRX.OQ   KPRX.O  is expected
to show
no change in quarterly revenue when it reports  results on March
21 (estimated) for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Kiora Pharmaceuticals
Inc is
for a loss of 42 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Kiora
Pharmaceuticals Inc is $3.00​, above​ its last closing price
of $0.60. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.34       -0.35      -0.89     Missed  -151.9
 Jun. 30 2023  -0.74       -1.07      -0.79     Beat    25.9
 Mar. 31 2023  -1.71       -1.68      -1.00     Beat    40.7​
 Dec. 31 2022  -2.23       -2.46      -1.76     Beat    28.6
 ​​Sep.        -3.68       -3.83      -6.03     Missed  -57.3
 30 2022                                                
 Jun. 30 2022  -8.00       -8.00      -7.20     Beat    10​
 Mar. 31 2022  -9.40       -9.40      -10.80    Missed  -14.9
 Dec. 31 2021              -9.20      -26.47    Missed  -187.7
 This summary was machine generated March 19 at 12:55 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)